Truist Securities maintains Insulet at Hold, raises price target to $160 from $153

Truist Securities kept Insulet at Hold but raised its price target to $160 from $153, a 4.6% increase. This implies a 9.2% upside from the Nov 6 close of $146.51. Recent analyst targets for Insulet range from $165 to $171.

Original reporting
Published Nov 9, 2026, 2:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Truist Securities maintains Insulet at Hold, raises price target to $160 from $153 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The upgrade could attract short-term buying interest but lacks a strong catalyst.

02

Market read

A single analyst upgrade with a modest target increase; limited impact on broader market.

03

What to watch

No new earnings or product news accompanies the target change.

Relevance 5/10Novelty 4/10Timing: today

Background

Truist Securities updated its valuation for Insulet, a medical device maker, reflecting a modestly higher outlook.

Market effects

None

None

None

Counterpoint

The price target raise may be overly optimistic given limited new operational data.

Key entities

  • Insulet

    Medical device manufacturer (ticker PINS)

  • Truist Securities

    Equity research firm providing the price target update

Related articles

$PODDMedAI 8/10

Insulet Corp (PODD) Q3 2026 Earnings Call Highlights: Revenue Up 19%, EPS Jumps 60%

Insulet Corp (PODD) reported Q3 2026 revenue up 19% and EPS up 60%. US new customer starts were flat, while global growth was low single-digits. The company expects 2027 growth to be modestly below mid-teens due to tougher comparisons and increased competition. Free cash flow for 2026 is expected to be $275 million. PBM negotiations for 2027 are ongoing, creating some uncertainty. The company plans to launch Omnipod 6 in 2027, with features aimed at improving clinical outcomes and lifestyle fit.